Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 10, 124 - 125 (2004)
doi:10.1038/nm0204-124
Lipid unites disparate syndromes of sepsis
Haichao Wang1, Christopher J Czura1 & Kevin J Tracey1,2
- Haichao Wang, Christopher J. Czura and Kevin J. Tracey are at North Shore–LIJ Research Institute, 350 Community Drive, Manhasset, New York 11030, USA.
- Kevin J. Tracey is a co-founder of Critical Therapeutics Inc., which develops experimental therapies that target critical care medicine. e-mail: kjtracey@sprynet.com
Abstract
Sepsis is by no means a single clinical entity; physicians must battle a variety of syndromes with only a vague notion of the molecular events that connect them. This vagueness now begins to dissipate with the identification of a molecule that can prevent the development of acute septic shock and severe sepsis (pages 161–167).
In 1347, a mysterious, horrifying disease arrived in Italy and then began to march across the European continent. By the time it reached Sweden three years later, the plague had filled 20 million graves—approximately one-third of the European population.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsisNature Medicine Article (01 Nov 2004)
Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged miceKidney International Original Article
Therapeutic effects of lysophosphatidylcholine in experimental sepsisNature Medicine Article (01 Feb 2004)
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrinThe EMBO Journal Article (21 Feb 2007)
